tiprankstipranks
Advertisement
Advertisement

CRVO Stock Latest News

CervoMed Completes Enrollment in Phase 2a Neflamapimod Trial
Company AnnouncementsCervoMed Completes Enrollment in Phase 2a Neflamapimod Trial
2d ago
8K
CRVO
CervoMed completes enrollment in neflamapimod study
PremiumThe Fly
CervoMed completes enrollment in neflamapimod study
2d ago
CRVO
CervoMed’s DLB Trial Milestone: What CRVO Investors Should Watch Next
PremiumCompany Announcements
CervoMed’s DLB Trial Milestone: What CRVO Investors Should Watch Next
3d ago
CRVO
CervoMed registers to sell 10.08M shares of common stock for holders
PremiumThe Fly
CervoMed registers to sell 10.08M shares of common stock for holders
5d ago
CRVO
CervoMed Raises $10 Million in Direct Offering
PremiumCompany Announcements
CervoMed Raises $10 Million in Direct Offering
19d ago
8K
CRVO
CervoMed announces $10M registered direct offering priced at-the-market
PremiumThe FlyCervoMed announces $10M registered direct offering priced at-the-market
23d ago
CRVO
CervoMed Gains New Patent for Neflamapimod Dementia Therapy
Premium
Company Announcements
CervoMed Gains New Patent for Neflamapimod Dementia Therapy
23d ago
8K
CRVO
CervoMed receives notice of allowance from USPTO on neflamapimod
Premium
The Fly
CervoMed receives notice of allowance from USPTO on neflamapimod
23d ago
CRVO
CervoMed Posts Updated Investor Presentation and Business Overview
PremiumCompany Announcements
CervoMed Posts Updated Investor Presentation and Business Overview
26d ago
8K
CRVO
CervoMed Announces Private Placement to Advance Neurology Pipeline
PremiumCompany Announcements
CervoMed Announces Private Placement to Advance Neurology Pipeline
1M ago
8K
CRVO
CervoMed announces $10.5M private placement
PremiumThe Fly
CervoMed announces $10.5M private placement
1M ago
CRVO
CervoMed announces $10.5M private placement
PremiumThe Fly
CervoMed announces $10.5M private placement
1M ago
CRVO
CervoMed Shareholders Back Board, Pay and Incentive Plan
PremiumCompany AnnouncementsCervoMed Shareholders Back Board, Pay and Incentive Plan
1M ago
8K
CRVO
CervoMed: FDA-Aligned Phase 3 Path and Multiple Catalysts Underscore Buy Rating, Price Target Held at $27
Premium
Ratings
CervoMed: FDA-Aligned Phase 3 Path and Multiple Catalysts Underscore Buy Rating, Price Target Held at $27
2M ago
CRVO
Boris Peaker Reiterates Buy on Neflamapimod Developer, Backs $20 Price Target on Pivotal DLB Phase III and Broad 2026 Clinical Catalysts
Premium
Ratings
Boris Peaker Reiterates Buy on Neflamapimod Developer, Backs $20 Price Target on Pivotal DLB Phase III and Broad 2026 Clinical Catalysts
2M ago
CRVO
CervoMed Highlights Q1 Results and Neflamapimod Progress
PremiumCompany Announcements
CervoMed Highlights Q1 Results and Neflamapimod Progress
2M ago
8K
CRVO
CervoMed price target lowered to $9 from $11 at Roth Capital
PremiumThe Fly
CervoMed price target lowered to $9 from $11 at Roth Capital
2M ago
CRVO
CRVO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
CRVO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
CRVO
Neflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed
PremiumRatings
Neflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed
3M ago
CRVO
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
PremiumCompany AnnouncementsCervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
3M ago
8K
CRVO
CervoMed presents neflamapimod MRI data
Premium
The Fly
CervoMed presents neflamapimod MRI data
3M ago
CRVO
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
Premium
Company Announcements
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
3M ago
8K
CRVO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >